General Mechanism of Action and Pharmacodynamics
Although Z-drugs are not chemically benzodiazepines, they exert their effects through the same receptor system. The molecules of these drugs bind to specific benzodiazepine sites and act as allosteric modulators.
As a result of this interaction, the sensitivity of GABA-A receptors to the primary inhibitory neurotransmitter of the central nervous system, gamma-aminobutyric acid (GABA), is increased. This leads to an increased frequency of chloride channel openings. Chloride ions ($Cl^-$) rapidly rush into the neuron, provoking hyperpolarization of the cell membrane. Potent inhibitory processes develop within the CNS.
Depending on the dosage, these drugs produce two main effects:
- Hypnotic (the primary therapeutic action);
- Sedative (manifested at lower doses).
Zaleplon and Zopiclone: Drug Profiles
Each representative of the group has a unique chemical structure and specific impact on sleep.
Zaleplon (Zaleplon) is a pyrazolopyrimidine derivative. It interacts with benzodiazepine sites on GABA-A receptors. The drug's main feature is its pronounced effect on sleep latency, significantly accelerating sleep onset. The medication provides a full eight hours of sleep, while its half-life is only 2 hours. Zaleplon is optimal for the short-term management of transient insomnia (typically 7 to 10 days).
Zopiclone (Zopiclone) belongs to the cyclopyrrolone derivatives. It is an intermediate-duration hypnotic. The effect appears within 20–30 minutes after administration and lasts about 6–8 hours. The drug binds to both $ω_1$ and $ω_2$ benzodiazepine receptors without significantly altering the total duration of rapid eye movement (REM) sleep. Its S-isomer, eszopiclone, is also used in clinical practice.
Among the specific adverse reactions of zopiclone, patients frequently report a characteristic bitter or metallic taste in the mouth. Nausea, irritability, depressed mood, and allergic reactions may occur. During the post-somnic period (upon awakening), dizziness and coordination disturbances can be observed. The withdrawal "rebound" phenomenon is mild. The drug is strictly contraindicated in children under 15, pregnant and breastfeeding women, and patients with decompensated respiratory failure.
Pharmacological Features of Zolpidem
Zolpidem (Zolpidem) is an imidazopyridine derivative. Like zopiclone, it is an intermediate-duration agent with a half-life ranging from 2 to 3 hours.
A key distinguishing feature of zolpidem is its high selectivity. It is a selective agonist exclusively for $ω_1$ benzodiazepine receptors. Consequently, it virtually does not distort sleep architecture. However, due to this high selectivity, zolpidem lacks the effects inherent to classic benzodiazepines:
- It does not act as a muscle relaxant;
- It does not produce an anxiolytic (anti-anxiety) effect;
- It exhibits no anticonvulsant activity.
Adverse effects associated with zolpidem include daytime drowsiness, headaches, and ataxia. Psychiatric disturbances such as hallucinations and nightmares are possible. The withdrawal rebound phenomenon is minimal.
Safety and Therapy Control
Despite their high efficacy, long-term use of Z-drugs is associated with serious risks. Regular use of zolpidem or zopiclone can lead to tolerance and marked drug dependence. To prevent these complications, the duration of continuous treatment is strictly limited and should not exceed 4 weeks.
In cases of acute overdose with zaleplon, zopiclone, or zolpidem, a specific antidote—flumazenil—is used in clinical practice. This drug acts as a competitive antagonist at benzodiazepine receptors, rapidly blocking them and reversing the toxic effects of the hypnotics.